Scalper1 News
Drug giant Teva Pharmaceutical Industries (TEVA) reported success in midstage testing for its new migraine drug Thursday, offering investors the first data on episodic migraine in particular. Results seemed to be in line with expectations, however, as the stock was flat in midday trading. Teva’s TEV-48125 is a CGRP antibody, one of a new class of migraine treatments also being developed by Alder Biopharmaceuticals (ALDR), Eli Lilly (LLY) and Amgen Scalper1 News
Scalper1 News